Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL4954723 | 0.86 | LTA4H (0.35) | SLC7A5DPP7DPP4PREPLTA4H | |
| SCHEMBL385711 | 0.86 | L3MBTL1 (0.36) | DPP7LTA4H | |
| SCHEMBL385712 | 0.86 | L3MBTL1 (0.36) | DPP7LTA4H | |
| SCHEMBL383046 | 0.84 | L3MBTL1 (0.39) | DPP7LTA4H | |
| SCHEMBL383047 | 0.84 | L3MBTL1 (0.39) | DPP7LTA4H | |
| Glycine SCHEMBL4955873 | 0.79 | GLRA1 (0.36) | DPP7LTA4H | |
| Serine SCHEMBL4956028 | 0.79 | DPP7 (0.40) | SLC7A5DPP7LTA4H | |
| SCHEMBL4958317 | 0.76 | CASR (0.34) | SLC7A5 | |
| Threonine SCHEMBL16111860 | 0.73 | SLC7A5 (0.63) | SLC7A5 | |
| Threonine SCHEMBL14946556 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | SLC7A5 2539/4885DPP7 173/4885DPP4 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.